Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term
October 30, 2015 10:14 AM EDTOn the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).
... MoreValeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference Call
October 30, 2015 8:53 AM EDTDown 7.6% currently, Valeant Pharma (NYSE: VRX) is on watch ahead of Bill Ackman's conference call, which is starting at 9:00AM ET.
During the call, Bill Ackman and other members of the Pershing Square investment team will address questions from investors... More
Valeant Pharma (VRX) Appoints Former U.S. Deputy AG Filip to Advise Ad Hoc Committee
October 30, 2015 8:46 AM EDTValeant Pharma (NYSE: VRX) announced that the ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's... More
